Skyrizi Pen
My Prescription
Payment
Select pharmacy
$22,812.09
Print or send this coupon to your phone
AlbertsonsPowered byAbout Skyrizi Pen
Drug Details
Risankizumab is prescribed for the treatment of plaque psoriasis and psoriatic arthritis, as well as specific bowel diseases like Crohn's disease and ulcerative colitis. As a monoclonal antibody, it functions by inhibiting interleukin-23, a natural protein in the body that can lead to inflammation and swelling.
Price history for Skyrizi Pen
1 Pen, 1ML of 150MG/ML
Average retail price for Skyrizi Pen
Average SaveHealth price for Skyrizi Pen
Our price history data is based on aggregated prescription data collected from participating pharmacies in America. Our prescription data updates daily to reflect the latest price changes. If you notice a missing data point, it means there wasn't sufficient data available to generate a monetary value for that date.
*Retail prices are based on pharmacy claims data, and may not be accurate when we don't have enough claims.
Skyrizi Pen dosage forms
| Dosage | Quantity | Price from | Per unit |
|---|---|---|---|
| 1ML of 150MG/ML | 1 Pen | $22,812.09 | $22,812.09 |
| 1ML of 150MG/ML | 2 Pens | $45,607.19 | $22,803.60 |
| 1ML of 150MG/ML | 3 Pens | $68,402.28 | $22,800.76 |
Skyrizi Pen FAQs
The SKYRIZI pen is a pre-filled injection device used to administer the medication risankizumab, which is prescribed for the treatment of certain inflammatory conditions such as plaque psoriasis. The pen is designed for ease of use, allowing patients to self-administer the medication subcutaneously, typically under the guidance of a healthcare provider.
SKYRIZI is used to treat moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. It is also approved for the treatment of active psoriatic arthritis in adults.
SKYRIZI is not approved for the treatment of Crohn's disease. It is primarily used for plaque psoriasis and psoriatic arthritis. For Crohn's disease, other medications are typically prescribed, and the dosing schedule for SKYRIZI would not be applicable. It is important to consult a healthcare provider for appropriate treatment options for Crohn's disease.
SKYRIZI pen is used to treat moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. It is also used for the treatment of active psoriatic arthritis in adults.
Weight loss is not commonly reported as a side effect of SKYRIZI (risankizumab-rzaa). If a patient experiences unexpected weight changes while taking this medication, it is advisable to consult with a healthcare provider to determine the cause and appropriate action.